Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Nivolumab: Targeting PD-1 to bolster antitumor immunity
Julie R. Brahmer
, Hans Hammers
,
Evan J. Lipson
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
117
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Nivolumab: Targeting PD-1 to bolster antitumor immunity'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Tumor Immunity
100%
Nivolumab
100%
Programmed Cell Death Protein 1 (PD-1)
100%
Melanoma Cells
28%
Renal Cell Carcinoma
28%
Non-small Cell Lung Cancer Cells
28%
Clinical Trials
14%
Advanced Melanoma
14%
Dacarbazine
14%
Metastatic Melanoma
14%
Phase II Trial
14%
Heavily Pretreated Patients
14%
Phase I Trial
14%
Anticancer Immune Response
14%
Objective Response Rate
14%
Improved Survival
14%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Japan
14%
Overall Survival Rate
14%
Multiple Cancers
14%
Previously Untreated Patients
14%
Human IgG4
14%
Fully Human
14%
Inhibitor Antibodies
14%
PD-1 Pathway
14%
T Cell Inhibition
14%
PD-1 Checkpoint Inhibitor
14%
Adverse Event Profiles
14%
Pharmacology, Toxicology and Pharmaceutical Science
Nivolumab
100%
Melanoma
42%
Non Small Cell Lung Cancer
28%
Renal Cell Carcinoma
28%
Adverse Event
14%
Clinical Trial
14%
Survival Rate
14%
Dacarbazine
14%
Metastatic Melanoma
14%
Overall Survival
14%
Phase I Trials
14%
Multiple Cancer
14%
Immunoglobulin G4
14%
Immune Checkpoint Inhibitor
14%
Phase III and IV Trials
14%